Undertreatment of menopausal symptoms and novel options for comprehensive management

被引:29
作者
Lewis, Vivian [1 ]
机构
[1] Univ Rochester, Med Ctr, Rochester, NY 14642 USA
关键词
Estrogens; conjugated; Hormone therapy; Menopause; Osteoporosis; Selective estrogen receptor modulators; Vasomotor symptoms; QUALITY-OF-LIFE; CONJUGATED EQUINE ESTROGENS; HORMONE REPLACEMENT THERAPY; VERTEBRAL FRACTURE RISK; MG; 17-BETA-ESTRADIOL; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; VASOMOTOR SYMPTOMS; BAZEDOXIFENE/CONJUGATED ESTROGENS; DOUBLE-BLIND;
D O I
10.1185/03007990903240519
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Objective: There is currently a gap in treatment options for menopausal symptoms and a need for comprehensive therapies that are safe and effective for postmenopausal women. This review discusses challenges in the management of menopausal symptoms and the effect of the Women's Health Initiative (WHI) study findings on current treatment patterns. It also examines present and future therapies. Research design and methods: A literature search was conducted using Medline, the Cochrane Database, and the National Heart Lung and Blood Institute WHI website with the following search terms: primary care, menopause, vasomotor symptoms, hormone therapy, osteoporosis, and vaginal atrophy. Searches were limited to articles published between 1995 and 2009. Results: Comprehensive therapies that target several aspects of menopause, such as vasomotor symptoms and chronic disease prevention, are currently hormone based. These hormone-based approaches are considered more effective than currently available nonhormonal therapies for the relief of menopausal symptoms. However, hormone therapy is not recommended for women at high risk for venous thromboembolic events, cardiovascular disease, and/or breast cancer. A need exists for novel therapies that mitigate menopausal symptoms, provide protection from osteoporosis, and encourage patient compliance without promoting cancer, heart disease, or stroke. Emerging modalities and strategies, such as the tissue selective estrogen complex (TSEC), Org 50081, MF101, and desvenlafaxine, may provide improved options for postmenopausal women. Conclusions: Several new menopausal therapies that may help to address the ongoing unmet need for safe and effective therapies for postmenopausal women are currently in development. In particular, the TSEC, which provides the benefits of both a selective estrogen receptor modulator and conjugated estrogens with an improved tolerability profile, may offer advantages over currently available treatment options. Limitations of this review include the narrow search criteria and limited search period.
引用
收藏
页码:2689 / 2698
页数:10
相关论文
共 95 条
[1]
A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms [J].
Adler, G ;
Young, D ;
Galant, R ;
Quinn, L ;
Witchger, MS ;
Maki, KC .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2005, 59 (04) :212-219
[2]
Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms [J].
Al-Azzawi, F ;
Buckler, HM .
CLIMACTERIC, 2003, 6 (02) :118-127
[3]
Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview [J].
Al-Baghdadi, O. ;
Ewies, A. A. A. .
CLIMACTERIC, 2009, 12 (02) :91-105
[4]
*AM COLL OBST GYN, 2004, OBSTET GYNECOL S, V104, pS1
[5]
Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[6]
[Anonymous], 2004, LANCET, V364, P2069
[7]
Drospirenone and estradiol: a new option for the postmenopausal woman [J].
Archer, D. F. .
CLIMACTERIC, 2007, 10 :3-10
[8]
Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women [J].
Archer, David E. ;
Lewis, Vivian ;
Carr, Bruce R. ;
Olivier, Sophie ;
Pickar, James H. .
FERTILITY AND STERILITY, 2009, 92 (03) :1039-1044
[9]
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding [J].
Archer, DF ;
Dorin, M ;
Lewis, V ;
Schneider, DL ;
Pickar, JH .
FERTILITY AND STERILITY, 2001, 75 (06) :1080-1087
[10]
The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women [J].
Arrenbrecht, S ;
Caubel, P ;
Garnero, P ;
Felsenberg, D .
MATURITAS, 2004, 48 (03) :197-207